# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(...
atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to tr...
Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Overweight.
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the ...
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.
Maxim Group analyst Jason McCarthy upgrades ATAI Life Sciences (NASDAQ:ATAI) from Hold to Buy and announces $6 price target.